Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Stalled U.S. tax reform, high deal premiums can't hobble pharma's M&A pace: expert
Stalled U.S. tax reform, high deal premiums can't hobble pharma's M&A pace: expert
Stalled U.S. tax reform, high deal premiums can't hobble pharma's M&A pace: expert
Submitted by
admin
on July 11, 2017 - 11:49pm
Source:
Fierce Pharma
News Tags:
tax reform
M&A
Headline:
Stalled U.S. tax reform, high deal premiums can't hobble pharma's M&A pace: expert
Do Not Allow Advertisers to Use My Personal information
